转移性黑色素瘤在新药治疗下的生存与费用更新:基于MelBase队列的估算
该研究基于法国MelBase前瞻性队列26家医院955例患者的数据,从医保支付方角度估算转移性黑色素瘤在新药上市后的生存与费用。结果显示平均生存时间增至23.6个月(95%CI:21.2;26.6),58%患者接受二线治疗,人均管理成本增至269,682欧元(95%CI:244,196;304,916),药物占总成本的80%。
要点
- 新药可及后转移性黑色素瘤患者平均生存时间增至23.6个月(95%CI:21.2;26.6)。
- 58%的患者接受了第二线治疗。
- 人均管理成本增至269,682欧元(95%CI:244,196;304,916),药物占总成本80%。
核心结论
- 随着突破性治疗药物进入一线及后续治疗线,转移性黑色素瘤的生存显著增加,但费用也显著增加,提出了财务可持续性问题。
研究设计与样本
- 基于前瞻性MelBase队列,收集26家医院955例患者从转移性疾病诊断至死亡的个体临床与经济数据。
- 生存采用Kaplan-Meier法估算。
- 费用从医保支付方角度按法国收费标准计算。
- 对存活患者,采用多状态模型根据患者预后因素和治疗线数外推5年病程以估算生存与费用。
主要发现
- 新药可及后转移性黑色素瘤患者平均生存时间为23.6个月(95%CI:21.2;26.6)。
- 58%的患者接受了第二线治疗。
- 人均管理成本为269,682欧元(95%CI:244,196;304,916)。
- 药物占总成本的80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice. METHODS: Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines. RESULTS: Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months (95%confidence interval [CI] :21.2;26.6), with 58% of patients receiving a second line of treatment. Mean management costs increased to €269,682 (95%CI:244,196;304,916) per patient. Drugs accounted for 80% of the total cost. CONCLUSION: This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability.
引用
- Kandel M, Allayous C, Dalle S, et al. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. Eur J Cancer. 2018. PMID: 30384014. doi:10.1016/j.ejca.2018.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。